Vanda Pharmaceuticals (VNDA) Research & Development (2010 - 2026)

Vanda Pharmaceuticals has disclosed Research & Development across 17 years of filings, most recently posting $28.4 million for Q1 2026.

• Research & Development for Q1 2026 came in at $28.4 million, down 20.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.1 million (down 92.0% YoY), and the FY2025 annual result was $14.4 million, down 80.65% from the prior year.
• Research & Development came in at $28.4 million for Q1 2026 at Vanda Pharmaceuticals, up from -$65.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $35.7 million in Q1 2025 to a low of -$65.9 million in Q4 2025.
• The 5-year median for Research & Development is $21.0 million (2022), against an average of $16.5 million.
• Peak annual rise in Research & Development reached 68.82% in 2025, while the deepest fall reached 431.98% in 2025.
• Vanda Pharmaceuticals' Research & Development stood at $18.5 million in 2022, then surged by 31.89% to $24.3 million in 2023, then declined by 18.48% to $19.8 million in 2024, then sank by 431.98% to -$65.9 million in 2025, then jumped by 143.17% to $28.4 million in 2026.
• The last three Research & Development figures came in at $28.4 million (Q1 2026), -$65.9 million (Q4 2025), and $22.6 million (Q3 2025), per Business Quant data.